A double‐blind, placebo‐controlled, single‐ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM15136 , a novel long‐acting glucagon analogue, in healthy subjects-Reference-Cited by-同舟云学术

A double‐blind, placebo‐controlled, single‐ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM15136 , a novel long‐acting glucagon analogue, in healthy subjects

Published:2021-11-24 Issue: Volume: Page:
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Huh Ki Young¹^ORCID,Hwang Jun Gi²^ORCID,Shin Wonjung³,BAEK Seungjae³^ORCID,Choi JaeDuk³,Lee Nora³^ORCID,Cho Young Min⁴^ORCID,Lee Howard¹⁵⁶⁷^ORCID

Affiliation:

1. Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Hospital Seoul South Korea

2. Department of Clinical Pharmacology and Therapeutics Chungbuk National University Hospital Cheongju‐si South Korea

3. Hanmi Pharmaceutical Co., Ltd Seoul South Korea

4. Department of Internal Medicine Seoul National University College of Medicine Seoul South Korea

5. Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology Seoul National University Seoul South Korea

6. Center for Convergence Approaches in Drug Development Seoul South Korea

7. Advanced Institutes of Convergence Technology Suwon South Korea

Funder

American Diabetes Association

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14590

Reference41 articles.

1. Novel Preparations of Glucagon for the Prevention and Treatment of Hypoglycemia